A good post somebody made and would like to share.
What I learned from today's PR:
1. BMSN application for IND was accepted by FDA with IND # posted for verification.
issuance of IND number 15376
2. BMSN also disclosed what they are working on right now:
As part of the clinical trial approval process, the FDA will issue comments on the proposed trial which must be addressed to the FDA's satisfaction before patient dosing is initiated.
3. BMSN is very sure about their team:
We have compiled an internationally-renowned team, consisting of corporate and academic partners, which cover the manufacturing, regulatory, and medical aspects of the project.
4. The next steps that are coming:
As part of the clinical trial approval process, the FDA will issue comments on the proposed trial which must be addressed to the FDA's satisfaction before patient dosing is initiated. The clinical trial will treat ten patients with aplastic anemia that have not responded to conventional therapy and lack a bone marrow donor.
5. What are our chances for final success:
HemaXellerate is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies.
6.And looking forward:
If the clinical trial is successful, the company plans to expand use of HemaXellerate™ to other conditions associated with bone marrow dysfunction, with the overall goal of entering the hematopoietic growth factor market.
7.Something to compare and evaluate this drug's market to:
This market is substantial in size and currently includes drugs such as Neupogen®, Neulasta®, Leukine® and Revolade®.
Conclusion:
BMSN IS NOT pump and dump pink company. They could easily over blow this PR, but instead disclosing to shareholders the present situation and step by step farther developments.
